These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27188274)

  • 1. Adoptive immunotherapy against ovarian cancer.
    Mittica G; Capellero S; Genta S; Cagnazzo C; Aglietta M; Sangiolo D; Valabrega G
    J Ovarian Res; 2016 May; 9(1):30. PubMed ID: 27188274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor infiltrating lymphocytes in ovarian cancer.
    Santoiemma PP; Powell DJ
    Cancer Biol Ther; 2015; 16(6):807-20. PubMed ID: 25894333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian Cancer Immunotherapy: Turning up the Heat.
    Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
    Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
    Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
    Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment.
    Liu J; Li H; Cao S; Zhang X; Yu J; Qi J; An X; Yu W; Ren X; Hao X
    J Immunother; 2014; 37(2):115-22. PubMed ID: 24509174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.
    Capellero S; Erriquez J; Melano C; Mesiano G; Genta S; Pisacane A; Mittica G; Ghisoni E; Olivero M; Di Renzo MF; Aglietta M; Sangiolo D; Valabrega G
    Sci Rep; 2020 Apr; 10(1):6478. PubMed ID: 32296104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.
    Helms MW; Prescher JA; Cao YA; Schaffert S; Contag CH
    Cancer Immunol Immunother; 2010 Sep; 59(9):1325-34. PubMed ID: 20532883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy against sarcomas.
    Mesiano G; Leuci V; Giraudo L; Gammaitoni L; Carnevale Schianca F; Cangemi M; Rotolo R; Capellero S; Pignochino Y; Grignani G; Aglietta M; Sangiolo D
    Expert Opin Biol Ther; 2015 Apr; 15(4):517-28. PubMed ID: 25516119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
    Ikarashi H; Fujita K; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
    Cancer Res; 1994 Jan; 54(1):190-6. PubMed ID: 8261438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.
    Genta S; Ghisoni E; Giannone G; Mittica G; Valabrega G
    Expert Opin Biol Ther; 2018 Apr; 18(4):359-367. PubMed ID: 29307234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.
    Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.
    Andersen R; Donia M; Westergaard MC; Pedersen M; Hansen M; Svane IM
    Hum Vaccin Immunother; 2015; 11(12):2790-5. PubMed ID: 26308285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive T cell therapy for ovarian cancer.
    Gitto SB; Ihewulezi CJN; Powell DJ
    Gynecol Oncol; 2024 Jul; 186():77-84. PubMed ID: 38603955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunotherapy of patients with ovarian cancer.
    Hwu P; Freedman RS
    J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
    Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
    Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer.
    Aoki Y; Takakuwa K; Kodama S; Tanaka K; Takahashi M; Tokunaga A; Takahashi T
    Cancer Res; 1991 Apr; 51(7):1934-9. PubMed ID: 2004379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.